- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02775864
Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This retrospective cohort study will use data from national (45-state) Medicaid Analytic Extracts data (2001-2010). The cohort will consist of adults who are 18 to 64 years old and diagnosed with schizophrenia who initiate a new psychotropic medication after a period of stable antipsychotic treatment.
The eligibility criteria select a cohort of individuals diagnosed with schizophrenia, have received antipsychotic monotherapy prior to the index date, and are still experiencing problems for which a new psychotropic medication strategy was initiated. A 1-year period of eligibility prior to follow-up initiation ensures sufficient time to collect service use related covariates to characterize cohort members.
Five clinical subgroups will be defined based on the presence of psychiatric diagnoses during the 30 days prior to and inclusive of the treatment change under study (index date) and who have this same diagnostic code from more than one provider to increase the validity of the diagnostic groups. The subgroups will be defined by codes to capture 1) uncomplicated schizophrenia; 2) schizoaffective disorder; 3) depression; 4) mania; and 5) anxiety. These subgroups are defined to reflect the reason for the change in treatment.
Pharmacological treatment options for patients with schizophrenia who are nonresponsive to antipsychotic monotherapy will include (1) initiation of a second antipsychotic, (2) initiation of an antidepressant, (3) initiation of a mood stabilizer and (4) initiation of a benzodiazepine.
The primary effectiveness outcome will be time to psychiatric hospitalization. Secondary measures include time to index treatment discontinuation, time to introduction of another psychotropic medication, psychiatric emergency department visits, all-cause hospitalization, and death.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
The data source will be national (45-state) Medicaid Analytic Extracts data (2001-2010). The cohort will consist of adults who are 18 to 64 years old and diagnosed with schizophrenia who initiate a new psychotropic medication after a period of stable antipsychotic treatment.
- Schizophrenia will be defined as ≥2 outpatient claims or ≥1 inpatient claim for schizophrenia [ICD-9-CM: 295] during 365 days of consecutive Medicaid enrollment immediately prior to the index date. Stable antipsychotic monotherapy will be defined by filled prescriptions for only one second-generation antipsychotic, and no other psychotropics, for ≥ 90 days immediately preceding the start of the index medication (t0). After the ≥90 days of stable treatment with a single second-generation antipsychotic, study patients will have had a change in therapy defined as (1) addition of a second antipsychotic or (2) addition of a different psychotropic drug class (antidepressant, mood stabilizer, or benzodiazepine). To ensure the patients are in active treatment there must be an active supply of antipsychotic medication on t0.
Exclusion Criteria:
- Medicare recipients
- Patients receiving clozapine
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Antipsychotic
Individuals initiating treatment with an antipsychotic medication
|
New initiation of any antipsychotic medication
|
Antidepressant
Individuals initiating treatment with an antidepressant medication
|
New initiation of any antidepressant medications
|
Benzodiazepine
Individuals initiating treatment with a benzodiazepine
|
New initiation of any benzodiazepine
|
Mood stabilizer
Individuals initiating treatment with a mood stabilizer
|
New initiation of lithium or any mood stabilizing anti-epileptic drug
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Psychiatric Hospitalization
Time Frame: One year
|
Number of participants hospitalized for a mental health reason
|
One year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Emergency Department Visit for Mental Health Reason
Time Frame: One year
|
Number of Participants with an Emergency Department visit for mental health reason
|
One year
|
Death
Time Frame: One year
|
Participants who died
|
One year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7226
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Antipsychotic
-
Fundación Marques de ValdecillaCentro de Investigación Biomédica en Red de Salud Mental; Instituto de Investigación...CompletedSchizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders | Schizophrenia RelapseSpain
-
University College, LondonCompletedSchizophrenia | Schizoaffective Disorder | Delusional Disorder | Schizophreniform DisordersUnited Kingdom
-
Western University, CanadaCompletedPregnancy Complications | Bipolar Disorder
-
Fayoum UniversityCompletedAntipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic PatientsSchizophrenia Spectrum and Other Psychotic Disorders | Periodontal DiseasesEgypt
-
Psychiatric University Hospital, ZurichRecruiting
-
Janssen-Cilag, S.A.CompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorder
-
Tianjin Anding HospitalCompletedSchizophrenia | Therapeutics
-
Nathan Kline Institute for Psychiatric ResearchTerminatedSchizophrenia | Schizoaffective Disorder
-
Herlev and Gentofte HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsRecruitingDeath, Sudden, Cardiac | Arrythmia | Antipsychotics and Neuroleptics ToxicityDenmark
-
University of Illinois at ChicagoNational Institute of Mental Health (NIMH)Terminated